報價延遲最少15分鐘:2026/07/18 23:15 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.93 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.30/--
|
|
企業價值
4.48B
|
| 資產負債 |
|
每股賬面淨值
12.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.10B
|
|
每股收益
0.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI)Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World. |
